CA3233408A1 - Imidazopyridazine il-17 inhibitor compounds - Google Patents

Imidazopyridazine il-17 inhibitor compounds Download PDF

Info

Publication number
CA3233408A1
CA3233408A1 CA3233408A CA3233408A CA3233408A1 CA 3233408 A1 CA3233408 A1 CA 3233408A1 CA 3233408 A CA3233408 A CA 3233408A CA 3233408 A CA3233408 A CA 3233408A CA 3233408 A1 CA3233408 A1 CA 3233408A1
Authority
CA
Canada
Prior art keywords
alkyl
compound
cycloalkyl
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3233408A
Other languages
English (en)
French (fr)
Inventor
Deane GORDON
Steven A. LOSKOT
Stefan MCCARVER
Steven P. Meduna
Timothy B. RHORER
Kristen SONG
Alexander E. VALDES
Dongpei Wu
Xiaohua XUE
Luke E. HANNA
Douglas C. Behenna
Steven D. Goldberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CA3233408A1 publication Critical patent/CA3233408A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3233408A 2021-09-27 2022-09-26 Imidazopyridazine il-17 inhibitor compounds Pending CA3233408A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163248566P 2021-09-27 2021-09-27
US63/248,566 2021-09-27
US202163273422P 2021-10-29 2021-10-29
US63/273,422 2021-10-29
US202263367546P 2022-07-01 2022-07-01
US63/367,546 2022-07-01
PCT/US2022/077001 WO2023049887A1 (en) 2021-09-27 2022-09-26 Imidazopyridazine il-17 inhibitor compounds

Publications (1)

Publication Number Publication Date
CA3233408A1 true CA3233408A1 (en) 2023-03-30

Family

ID=83692741

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3233408A Pending CA3233408A1 (en) 2021-09-27 2022-09-26 Imidazopyridazine il-17 inhibitor compounds

Country Status (16)

Country Link
US (2) US12173007B2 (cg-RX-API-DMAC7.html)
EP (1) EP4408847A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024536869A (cg-RX-API-DMAC7.html)
KR (1) KR20240082369A (cg-RX-API-DMAC7.html)
AU (1) AU2022349687A1 (cg-RX-API-DMAC7.html)
CA (1) CA3233408A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000867A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024003723A2 (cg-RX-API-DMAC7.html)
DO (1) DOP2024000051A (cg-RX-API-DMAC7.html)
IL (1) IL311751A (cg-RX-API-DMAC7.html)
JO (1) JOP20240059A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024003772A (cg-RX-API-DMAC7.html)
PE (1) PE20240935A1 (cg-RX-API-DMAC7.html)
TW (1) TW202330530A (cg-RX-API-DMAC7.html)
UY (1) UY39958A (cg-RX-API-DMAC7.html)
WO (1) WO2023049887A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022349687A1 (en) 2021-09-27 2024-05-16 Janssen Pharmaceutica Nv Imidazopyridazine il-17 inhibitor compounds
US12024507B2 (en) 2021-10-25 2024-07-02 Terns Pharmaceuticals, Inc. Compounds as GLP-1R agonists
TW202430165A (zh) 2022-12-02 2024-08-01 丹麥商理奧藥品公司 Il-17之小分子調節劑
AU2024213283A1 (en) * 2023-01-30 2025-08-14 Dice Alpha, Inc. Benzimidazole and aza-benzimidazole based il-17a modulators and uses thereof
EP4688156A1 (en) * 2023-03-28 2026-02-11 Janssen Pharmaceutica NV Lactam-containing imidazopyridazine il-17 inhibitor compounds
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
WO2024215597A1 (en) * 2023-04-11 2024-10-17 Dice Alpha, Inc. Substituted 6-imidazopyridazine il-17a modulators and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111601799B (zh) * 2018-01-15 2023-06-09 Ucb生物制药有限责任公司 作为Il-17调节剂的稠合咪唑衍生物
TWI752400B (zh) * 2019-01-07 2022-01-11 美商美國禮來大藥廠 Il-17a抑制劑
GB201909190D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
CN112341450B (zh) * 2019-08-09 2022-05-17 成都先导药物开发股份有限公司 一种免疫调节剂
WO2021098844A1 (zh) * 2019-11-20 2021-05-27 成都先导药物开发股份有限公司 一种免疫调节剂
WO2021170627A1 (en) * 2020-02-25 2021-09-02 UCB Biopharma SRL Difluorocyclohexyl derivatives as il-17 modulators
JP7664947B2 (ja) 2020-04-30 2025-04-18 ヤンセン ファーマシューティカ エヌ.ベー. Il-17の調節因子としてのイミダゾリダジン
WO2023025783A1 (en) 2021-08-23 2023-03-02 Leo Pharma A/S Small molecule modulators of il-17
AU2022349687A1 (en) 2021-09-27 2024-05-16 Janssen Pharmaceutica Nv Imidazopyridazine il-17 inhibitor compounds
CN116143777A (zh) 2021-11-04 2023-05-23 四川海思科制药有限公司 一种可抑制il-17a的杂环化合物及其用途

Also Published As

Publication number Publication date
TW202330530A (zh) 2023-08-01
JOP20240059A1 (ar) 2024-03-26
WO2023049887A1 (en) 2023-03-30
CO2024003723A2 (es) 2024-04-18
PE20240935A1 (es) 2024-04-30
JP2024536869A (ja) 2024-10-08
KR20240082369A (ko) 2024-06-10
UY39958A (es) 2023-04-28
US20230143050A1 (en) 2023-05-11
AU2022349687A1 (en) 2024-05-16
MX2024003772A (es) 2024-06-19
DOP2024000051A (es) 2024-11-15
CL2024000867A1 (es) 2024-09-23
EP4408847A1 (en) 2024-08-07
US20250109137A1 (en) 2025-04-03
IL311751A (en) 2024-05-01
US12173007B2 (en) 2024-12-24

Similar Documents

Publication Publication Date Title
CN107949559B (zh) 作为irak4调节剂的双环稠合杂芳基或芳基化合物
AU2019203476B2 (en) Pyrimidinyl tyrosine kinase inhibitors
US12173007B2 (en) Imidazopyridazine IL-17 inhibitor compounds
JP7398391B2 (ja) N-[4-オキソ-2,3-ジヒドロ-1,5-ベンズオキサゼピン-3-イル]-5,6-ジヒドロ-4H-ピロロ[1,2-b]ピラゾール-2-カルボキサミド誘導体及び例えば過敏性腸症候群(IBS)を処置するためのRIP1キナーゼ阻害剤としての関連化合物
ES2718552T3 (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de IRAK4
US12215111B2 (en) Imidazopyridazine IL-17 inhibitor compounds
JP5977819B2 (ja) C型肝炎ウイルス阻害剤
CN111386275B (zh) 高活性sting蛋白激动剂
CA3181793A1 (en) Imidazopyrimidines as modulators of il-17
KR20200030558A (ko) 이환형 케톤 화합물 및 이의 사용 방법
US9561212B2 (en) Hepatitis C virus inhibitors
WO2024201322A1 (en) Lactam-containing imidazopyridazine il-17 inhibitor compounds
EA049269B1 (ru) Соединения ингибиторов il-17 на основе имидазопиридазина
WO2025202931A1 (en) Imidazopyridazine il-17 inhibitor compounds
RU2845865C2 (ru) Нитрилсодержащие противовирусные соединения
WO2025202922A1 (en) Imidazopyridazine il-17 inhibitor compounds
CN118317962A (zh) 咪唑并哒嗪il-17抑制剂化合物
HK1254323B (en) Bicyclic-fused heteroaryl or aryl compounds as irak4 modulators
HK1209284B (en) Pyrimidinyl tyrosine kinase inhibitors

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240806

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240806

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250805

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250805

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260804

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260804